DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.

Open source

DOI
10.1158/1078-0432.ccr-25-0874
Published
2026-03-01
Container
Clin Cancer Res
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-0874,
  title = {DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.},
  author = {Jhaveri K and  Loi S and  Hamilton E and  Schmid P and  Anders CK and  Testa L and  Wildiers H and  Tseng LM and  Lu YS and  Park YH and  Im SA and  Chen SC and  Young RR and  Lloyd C and  Wrona M and  Zhang C and  Carroll D and  André F.},
  year = {2026},
  journal = {Clin Cancer Res},
  doi = {10.1158/1078-0432.ccr-25-0874},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-0874}
}

RIS

TY  - JOUR
TI  - DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.
AU  - Jhaveri K
AU  -  Loi S
AU  -  Hamilton E
AU  -  Schmid P
AU  -  Anders CK
AU  -  Testa L
AU  -  Wildiers H
AU  -  Tseng LM
AU  -  Lu YS
AU  -  Park YH
AU  -  Im SA
AU  -  Chen SC
AU  -  Young RR
AU  -  Lloyd C
AU  -  Wrona M
AU  -  Zhang C
AU  -  Carroll D
AU  -  André F.
PY  - 2026
JO  - Clin Cancer Res
DO  - 10.1158/1078-0432.ccr-25-0874
UR  - https://doi.org/10.1158/1078-0432.ccr-25-0874
ER  - 

APA

K, J., S, L., E, H., P, S., CK, A., L, T., H, W., LM, T., YS, L., YH, P., SA, I., SC, C., RR, Y., C, L., M, W., C, Z., D, C., & F., A. (2026). DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-25-0874

Source records